Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | MAOA | P21397 | 4/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | SDHA | P31040 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CALML3 | P27482 | 1/20 | 0.60 |
| ▸ | F10 | P00742 | 10/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337870 | 0.93 | MAOA (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6478092 | 0.93 | MAOA (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6337549 | 0.86 | MAOA (0.51) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7704289 | 0.84 | MAOB (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7704284 | 0.84 | MAOB (0.63) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5102273 | 0.83 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5102282 | 0.83 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5112681 | 0.83 | KCNH2 (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5111227 | 0.83 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5111223 | 0.83 | MAOB (0.62) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385834-B1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO INC (US) | 2005-09-14 | — | — | EP | claimed |
| US-6897230-B2 | Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-24 | — | — | US | claimed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | claimed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| EP-1385834-B1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6897230-B2 | Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | disclosed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | NR4A1, NR0B1, NR1D1 | MAOB 3207/4885MAOA 3466/4885PTGS1 2599/4885 |
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | NR0B1, NR4A1, VDR | MAOB 2427/4885MAOA 2194/4885PTGS1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.